New Imaging Techniques Uncover How Dual Agonist Drugs Target Brain and Pancreas for Diabetes and Obesity
The article discusses the development of fluorescent probes, daLUXendin544 and daLUXendin660, which specifically target GLP1R and GIPR receptors in the pancreas and brain, enabling detailed visualization of cell targets and receptor nanodomains, and providing insights into the cellular mechanisms of dual agonists like tirzepatide for diabetes and obesity treatment.